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Abstract 
We have developed a new protocol for using Molecular Inversion Probes (MIP) to 
accurately and specifically measure allele copy number (ACN).   The new protocol 
provides for significant improvements including the reduction of input DNA (from 2µg) 
by more than 25 fold (to 75ng total genomic DNA), higher overall precision resulting in 
one order of magnitude lower false positive rate, and greater dynamic range with accurate 
absolute copy number up to 60 copies. 
 
Background 
Chromosomal copy number analysis has been important in the study of tumor samples 
for decades.  Changes in copy number have already been demonstrated to predict 
patients’ response and/or prognosis, [1] which gives hope that this can be applied in large 
scale to significantly affect clinical care in the future.  In order to fulfill this promise, 
technologies that are able to assess copy number on the whole genome scale in a large 
number of samples are required.  Since the development of Comparative Genomic 
Hybridization (CGH), [2] many technologies have been developed to address this need.  
These include Bacterial Artificial Chromosome (BAC) CGH and more recently CGH 
employing several types of oligonucleotides arrays [3-7]. Some of the newer CGH 
methodologies allow for allelic information to be obtained [4, 5, 7, 8]. The utility of 
measurement of allele copy number include the identification of loss of heterozygosity 
(LOH) events [4] and the allelic composition at amplified loci [9]. 
One of the techniques that have previously been described for the measurement of allele 
copy number is molecular inversion probes (MIP) [10, 11].  Briefly MIP probes are 
circularizable oligonucleotides, where the two ends carry two sequences that are 
complementary to two sequences on the genome separated by one nucleotide (exactly 
where the variant to be genotyped is).  After hybridization to the genomic DNA, the 
reaction is split into 4 tubes where a single nucleotide is added to each tube.  Upon the 
addition of the nucleotide (only in the tube with the nucleotide that is complementary to 
the allele on the genome) the MIP probe is then ligated turning the probe into a circle.  
This structure can be selected for by the use of exonucleases allowing for minimal “cross 
talk” between probes and the ability to obtain high quality data from highly multiplexed 
assays (>50,000 plex).  Ultimately these products are amplified and hybridized onto an 
Affymetrix microarray to identify the present products.   
 
The MIP assay differs from other highly multiplexed (10,000s-100,000s) techniques in 
that it utilizes enzymatic steps in solution to capture specific loci, which is then followed 
by an amplification step. Such combination of enzymatic steps confers a high degree of 
specificity on the MIP assay.High specificity and minimum “cross talk” between loci or 
alleles results in precise measurements as well as large assay dynamic range.  In addition 
the amplification of the loci of interest only simplifies the task of detection and provides 
the ability to use lower amounts of input genomic DNA.  The high precision, large 
dynamic range, and low DNA usage are demonstrated in this study.  Finally, because 
MIP requires only 40 bp of intact genomic DNA, its use in degraded samples, like 
Formaldehyde Fixed Paraffin Embedded (FFPE) may offer distinct advantages.   
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We have made significant advancements in this technology.  As a result, the false 
positive rate decreased by an order of magnitude and the dynamic range extended to 
achieve accurate absolute copy number measurements up to 60 copies, while reducing the 
input genomic DNA  requirement by more than 25 folds. 
 
We describe the performance of the MIP assay using several types of metrics that are 
broadly useful to all copy number assays: (1) the ability to discriminate a copy number 
aberration from normal at a total as well as allelic copy number level, and (2) the ability 
to accurately quantitate the level of copy number aberration at both total and allelic copy 
number levels. 
 
Results 
MIP copy number assay modification 
We have previously described the use of MIP for copy number analysis [10].  We have 
now improved the performance of the technology through modifications of the MIP copy 
number protocol and through improved data analysis.  The improved performance allows 
allele copy number data to be obtained using 75ng of human genomic DNA.   
The first implementation of the MIP ACN assay required 2µg of genomic DNA.  We 
discovered that only a fraction of the genomic templates hybridized to MIP probes that 
are then circularized and amplified.  We hypothesized that increasing the number of MIP 
molecules and decreasing the hybridization volume should increase the number of MIP 
molecules bound to their genomic targets.  We tested this hypothesis and verified that 
increasing the number of MIP molecules by a factor of four and decreasing the 
hybridization volume (from 27 µl to 6.7 µl) allowed us to substantially decrease genomic 
DNA input.  After the hybridization, buffer is added to increase the volume to 27 µl, and 
the rest of the protocol is unmodified.  
In the standard genotyping protocol genomic target is split into 4 reactions, where one of 
each of the 4 nucleotides is added.  We recognized that we could decrease DNA input 
requirements by performing a smaller number of these reactions We reasoned that if we 
were to only use one set of SNPs (for example only the most common C/T SNPs), we 
would decrease the DNA requirement by 50%.  Similarly, adding two nucleotides into 
each of two reactions leads to the same result.  We have implemented this variant 
protocol by adding G and C nucleotides into one tube, and adding A and T into another.  
In this scenario, about 85% of SNPs in the human genome (all but G/C and A/T SNPs) 
can be assessed.  An advantage of decreasing the number of reactions is that it requires 
only two independent readouts rather than four (i.e., 4 colors on 1 array or 1 color on 4 
arrays). In the optimized procedure, 75 ng genomic DNA is mixed with more than 50,000 
probes in a small volume (6.7 µl).  The hybridized probe:target genomic DNA are split 
into two reactions, where 2 nucleotides are added to each of the two tubes. The two 
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reactions are processed separately and read on two independent arrays, which was found 
to yield better data than two colors on one array (data not shown).     
One effect that requires correction in quantitative assays on arrays is the phenomenon of 
saturation.  This is especially important for correct estimations of amplifications.  We 
have implemented a Langmuir correction for the non-linear relationship between signal 
and copy number [15].  Our algorithm was developed on a separate data set, and the data 
shown here is an independent set.  Using this algorithm we have been able to measure 
copy number in a linear fashion at levels over 60 copies (see below).     
Detection of aberrations: 
An important aspect of the copy number performance is the detection of aberrations 
where the copy number is distinct from 2.  The degree of discrimination between copy 
number 2 and the aberrant copy can be understood through ROC curves showing the 
trade off between false positive and sensitivity (1-false negative rate) given data on 
regions with known copy number. The presence of cell lines carrying 1,3,4, or 5 X 
chromosomes provides a good resource for the study of the performance of the 
technology in this copy number range [2].  For example in the assessment of the cell lines 
with one X chromosome (males) one can make a threshold at copy number 1.5 and any 
marker on the X chromosome with a copy number below 1.5 would be considered a true 
positive, and any autosomal marker with a copy number below 1.5 is considered a false 
positive.  By plotting this trade off between true and false positives at many thresholds 
between copy numbers of 0 to 3 the full ROC curve is generated.  
To assess the ability of MIP to detect copy number aberrations we used a probe panel 
containing ~53,000 single nucleotide polymorphisms (SNP). We utilized this pool to 
assay 63 samples (45 unique, 9 duplicate) from the 3 major populations used in the 
HapMap project.  Out of the 53,341 SNPs, 50,806 had genotyping call rates of greater 
than 90%. We then sorted the remaining SNPs based on the standard deviation of their 
predicted copy number. We selected the most robust markers for detailed study of copy 
number performance by selecting those with a standard deviation of less than 12%.  This 
yielded a population of 39,785 markers.  Figure 1 shows the copy number estimates 
across the genome for the different samples carrying 1-5 copies of the X chromosome.  
By assuming that males have only one copy of the X chromosome markers and two 
copies of autosomal markers, we generated ROC curves to describe the trade off between 
false positive and sensitivity for distinguishing one copy from two copies (Figure 2, red 
line).  Similar ROC curves can be generated for the discrimination between 2 and 3, 4, or 
5 copies (Figure 2).  By comparing the generated ROC curves with our published data for 
previous MIP protocol we find a dramatic improvement.  For example, at the same 50% 
sensitivity level, we found a reduction of the false positive rate by an order of magnitude.   
The ROC curve above describes the average performance of a set of samples.  We also 
wished to understand the performance of individual samples.  As can be seen in Figure 3, 
individual samples have different false positive rates given the same sensitivity level.   
Similarly ROC curves can be generated to assess the ability to study allele copy number. 
For example Figure 4 depicts the ROC curve to assess the ability to discriminate the 
usual 1:1 ratio in heterozygotes from 2:1 ratio on the X chromosome in a cell line 
carrying 3X chromosomes.  The ROC curve for allele ratio is not as good: at a sensitivity 
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level of 50%, the copy number false positive rate is ~ 1x10-3, and the allele ratio false 
positive rate is ~8x10-3.  One reason for this discrepancy is that we are using the best 
markers as defined by copy number root square deviation (RSD).  The use of the best 
markers as defined by an allele ratio criteria (allele ratio RSD) significantly improves the 
performance (sensitivity of 50% and false positive rate of ~3x10-3 
Systematic false positives 
The above analysis assumes that all the autosomal markers are present at two copies per 
cell.  There has been a wealth of evidence demonstrating copy number polymorphisms 
(CNP) in the general population [12, 13].  Therefore a fraction of what we considered as 
false positive may in fact be true positives.  In addition, the presence of a secondary SNP 
(distinct from the one being interrogated) within the probe may emulate the presence of a 
deletion.  Data generated on two CEPH pedigree populations, Yoruban and Utah, is 
informative in this regard because the polymorphism on which the MIP panel are based 
are from European (equivalent to Utah) rather than African populations. The contribution 
of genetic variants (CNP or SNP) to the apparent false positive rate is suggested by our 
detection of ~ 3 fold more apparent autosomal deletions in the Yoruban population 
compared to the Utah population (average number of markers per sample with measured 
copy number below 1.3 is 126 markers for Utah population and 319 for Yoruban 
population). We hypothesized that this imbalance between the number of apparent 
deletions in the two populations was likely due to secondary polymorphisms close to the 
SNP being assayed which prevent proper binding of the MIP to its target. Further 
evidence to support this hypothesis was noted when we observed that the majority of 
these apparent deletions were reproducible when a sample is re-assayed.  
To understand the nature of these apparent deletions we randomly picked ten SNPs, 
which showed copy number measurements below 1.3 in replicate measurements from the 
Yoruba sample (sample NA18515). We PCR amplified ~400 basepair fragments that 
included the SNP assayed by MIP and used dideoxy sequencing to show that eight of 
these nine loci that were successfully sequenced had a secondary SNP within the MIP 
probe homology sequence.  The ninth SNP that showed copy number 1 was assayed by 
qPCR to measure copy number but was found to show a normal copy number of two 
(Supplementary Table 1).  
Trade off between resolution and performance 
Copy number changes are expected to occur in discrete segments allowing neighboring 
markers to be averaged together.  This leads to enhanced performance as measured by 
trade off between false positive and sensitivity (i.e. ROC curve moving to the upper left) 
at the expense of lower resolution.   
As discussed above, one shortcoming of the ROC analysis is the presence of CNPs in the 
autosomes.  Averaging two adjacent markers that lie within a CNP will erroneously 
consider these markers as false.  Therefore for the purpose of describing the performance 
of the technology we averaged markers that are not adjacent for each other.  This method 
would ameliorate the effect of miscalling two adjacent markers in a CNP as a false 
positive.  This analysis is appropriate as long as there is a lack of correlation between 
marker performance and the position on the chromosome.  If this assumption is true then 
the operation reflects the performance of averaging two adjacent markers since the 
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adjacent and the random markers are obtained from the same distribution.  Clearly 
averaging data from non-adjacent markers is only valid for the assessment of the 
technology performance and cannot generate any meaningful biological findings.     
Averaging over two markers improves the performance of the MIP data significantly 
(Figure 5). Clearly when one is trying to obtain biological information smoothing non-
adjacent markers is totally erroneous.  In this case we were interested in the exact 
opposite: erasing any real biological information (copy number polymorphisms) and 
hence we smoothed across non-adjacent markers.  For the discrimination between 1 and 2 
copies, a sensitivity level of 80% and a false positive rate of 5x10-5 can be achieved.   
The ROC curves shown in the above figures describe the performance of the top ~75% of 
the markers in the panel we constructed.  It is expected that as more of the lower quality 
markers are considered, the ROC performance will decrease.  We included ~48,000 
markers (~90% of the total) in the analysis.  Figure 5 shows the ROC curve to 
discriminate one from two copies using one marker or two markers using 75% (40K) or 
90% (48K) of the data.  As can be seen in Table 1 the average performance with 90% of 
the markers is somewhat worse than that seen with 75% of the markers when judging the 
specificity at 50% sensitivity.  
Accuracy of copy number estimation 
The ROC curves describe the discrimination between two copies and a specific 
aberration.  However it does not define the accuracy of the copy number estimation.  The 
accuracy of the copy number determination can be estimated by the deviation from the 
true copy number.  This can be readily measured for 1-5 copies using the X chromosome 
series.  As can be seen in Table 2, the copy number estimation in the MIP data is very 
close to the true value.  The precision, as defined by the relative standard deviation, over 
the 1-5 copy number range is 0.1-0.14.     
Accuracy of copy number estimation at high copy number amplification can be assessed 
by comparing the MIP estimation with real time PCR measurement.  We have done such 
a calibration for a selected amplification in cell line MCF7 (Figure 6).  The average copy 
number estimate among 30 MIP markers within the amplification is 43, which is close to 
the 33 copies measured by real time PCR.  Copy number estimation is computed relative 
to a “control” region in the genome.  In cancer cell lines, the “control” region used in real 
time PCR may not have the average ploidy of the cell and therefore may bias the 
estimation of the amplified region.  In fact in this example the control region was from 
chromosome 2, which is estimated to be present at slightly elevated copy numbers 
compared to the average of the genome based on the MIP data. Correcting for this bias 
would make the MIP and real time PCR copy number estimation of the amplification 
even closer. 
To carefully assess the accuracy of the measurement at high copy number values, we 
added a known quantity of a set of PCR amplicons to a normal sample before the MIP 
reaction was performed.  The DNA fragments that were spiked in were added at different 
copy number levels ranging from no extra copies to several hundred additional copies. 
Supplemental Table 2 shows the PCR amplicons, the MIP probes they correspond to, and 
the spike in levels.  We show the relationship between the expected and the measured 
copy number of either the individual spikes (Figure 7). 
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Accuracy of measurement of allele copy number in amplification sites for many methods 
is limited by allele cross talk.  Allele cross talk is the proportion of signal measured for 
one allele in the presence of a second allele.  To assess this phenomenon using MIPs we 
studied the spike in data.  The spiked in PCR amplicons were purposely generated from 
an individual that is homozygous and added into DNA from a heterozygous individual 
making the copy number for one allele 1 and the other ranges from 1 to 1,000.  The allele 
cross talk in the MIP assay is very low, as the presence of 100 copies or more of one 
allele does not change the copy number of the other allele significantly (Table 3). 
Identification of LOH without Matched Normal Tissue 
A major challenge in the study of ACN is the absence of matched normal tissue for many 
valuable clinical samples. In tumors that have lost one allele, it is not easy to discriminate 
LOH for individual alleles that are homozygous in the entire individual. We recognized 
that the high sensitivity and accuracy of the MIP ACN assay, coupled with the high 
likelihood of normal tumor contamination, could allow us to distinguish LOH from 
alleles that are homozygous. In theory, this should be best accomplished with tumor 
showing substantial (approaching 50%) normal contamination. 
To test this theory, we analyzed ACN from 5 breast tumors using the 60K MIP panel. 
Visual examination of the data clearly show a typical plot of estimated copy number for 
allele A vs. allele B, compared to a tumor with relatively normal genome structure 
(Figure 8A). Three clusters are expected in such a plot, one at ~2,0 (homozygous A), one 
at 0, ~2 (homozygous B), and one at ~1, ~1 (heterozygous). In the aberrant tumor 
samples (Figure 8B, C), three distinct clusters can be observed in the heterozygous 
cluster.  The central cluster represents the “true” heterozygous copy number 
measurements.  The flanking clusters represent LOH of either the A or B allele. These 
sub-clusters of the heterozygous cluster clearly resolve into discrete copy number 
segments along the chromosome as can be seen in Figure 9. We are also able to observe 
that deletions are observed not as zero copies for each allele, but as ~0.5 copies of each 
allele (Figure 9D). To assess reproducibility, we analyzed all samples in duplicate and 
calculated concordance estimates for the various genotypes (Table 4). 
 
Discussion 
We describe in this manuscript significant improvements we have made to the MIP-based 
measurements of ACN.  By increasing the proportion of genomic targets that are 
hybridized to the MIP probes, we have improved the performance while requiring a 
smaller amount of DNA.  Additionally, for copy number measurements there are 
substantial advantages in uniformity and robustness when utilizing one-color readouts, 
especially at high levels of multiplexing.  The use of a control sample that is co-
hybridized with the test sample in an analogous fashion as used by BAC arrays leads to 
inferior results compared with the one color readout (data not shown).  Presumably this is 
because the different dyes have different characteristics of brightness and saturation.  We 
conclude that the effect of the lack of uniformity among the dyes is probably larger in our 
system than chip-to-chip variation that the control sample co-hybridization is supposed to 
ameliorate.  The improvements achieved from the new protocol as evaluated by ROC 
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curve analysis resulted in a decline in the false positive rate by an order of magnitude, 
while reducing the input genomic DNA by more than 25 fold.  In addition the dynamic 
range has been extended with accurate estimation achieved for up to 60 copies.       
We evaluated the performance of MIP for ACN measurements using a set of metrics that 
are broadly useful for all copy number assays. We demonstrate the ability of MIP to 
detect a single copy deletion or duplication at allele and total copy number using ROC 
curve analysis.  We believe ROC curve analysis provides a rigorous statistical framework 
for comparing different technologies or different protocols/algorithms of the same 
fundamental technology.  In addition to genuinely improving the technology performance 
in the ROC curves by the use of better protocol and algorithms, one may apparently 
improve them by smoothing (figure 5), filtering the worst markers (figure 5), or the worst 
samples (figure 3).   
 
We have shown in the single MIP marker analysis that many of the apparent false 
positives in the discrimination between 1 and 2 copies are due to the presence of SNPs in 
the genomic sequence that are complementary to the MIP probes.  This effect will be 
strongest in the populations that are most diverse. It should be possible to ameliorate this 
effect by using matched normal and tumor pairs.  The presence of SNPs may explain why 
the discrimination between 1 and 2 is not better than that between 2 and 3, as secondary 
SNPs that interfere with MIP binding emulate a copy number deletion.   
We also show the MIP assay precision of measurements of copy number at allele and 
total copy number.  Precision at the total copy number requires low background of the 
assay and lack of saturation.  In addition the allele level precision requires low level of 
allele cross talk even when one allele is present in huge excess relative to the other.  
These observations led us to suspect that it should be possible to genotype mixed DNA 
populations, such as occurs in tumor samples contaminated with normal tissue. As 
normal contamination increases some estimate of the amount of normal contamination is 
valuable, which we believe can be quite accurately estimated using the calculated copy 
numbers for regions of LOH and deletion. 
One promise of ACN data over the traditional total copy number data is the potential that 
it may facilitate the identification of the critical genes in regions of aberrations. Even 
though large aberrations can be readily identified by total copy number CGH, the 
identification of the critical gene(s) in these aberrations is often not straightforward.  This 
is in contrast to sequencing data where identification of mutations has been quite 
laborious, but once achieved the critical gene is usually easily identified.  Identification 
of an allele that is preferentially deleted or amplified in a set of samples implicates the 
specific allele (or one in linkage disequilibrium with it) as critical in the pathogenesis of 
the aberrations.  The one example in the literature may be supplemented by assessment of 
allele copy number in a large number of SNPs in different sets of cancer samples. 
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Material and Methods 
Samples and MIP assay: 
The normal samples as well as the samples carrying 3 (NA04626), 4 (NA01416), and 
5(NA06061) copies of the X chromosome were obtained from Coriell Cell Repository 
(Camden, NJ).  The normal HapMap samples that were used were also obtained from 
Coriell Cell Repository.  The samples that were used were: NA19240, NA19239, 
NA06991, NA06985, NA19238, NA19222, NA19202, NA19201, NA19200, NA19132,  
NA19131, NA18956, NA18951, NA18949, NA18947, NA18945, NA18912, NA18854, 
NA19130, NA19128, NA19127, NA19099, NA19094, NA18991, NA18987, NA18981, 
NA18605, NA18603, NA18582, NA18573, NA18558, NA18550, NA18547, NA18542, 
NA18537, NA18515, NA18508, NA12892, NA12813, NA12717, NA12156, NA12155, 
NA12004, NA11881, NA11840, NA11832, NA11830, NA10831, NA07345, NA07056, 
NA07029, NA07019, NA07000, and NA06993.  The MCF7 cell line was obtained from 
the American Tissue Cell Culture (ATCC).  
 
The MIP assay was performed as described previously, but with important modifications 
[14].  Specifically, the current protocol is a modification of the Targeted Genotyping 
protocol commercialized by Affymetrix (Additional information about MIP technology 
can be found at the Affymetrix website, 
http://www.affymetrix.com/products/application/targeted_genotyping.affx).  Briefly, 
test DNA samples were diluted to 16ng /µl.  All DNA quantitation is done using 
PicoGreen dsDNA Assay Kit (Molecular Probes / Invitrogen, P7589).  96 or 384 well 
plates were used whenever possible to reduce variation.  For day1 overnight annealing, 
4.7 ul of DNA samples (75ng total), 0.75ul of Buffer A, 1.1 ul of the 53K probe pool 
(200 amol/ul/probe) and 0.045 ul of Enzyme A were mixed well in a 384-well plate on 
ice.  The reaction was incubated at 20○C for 4 min, 95○C 5 min, then 58○C overnight. On 
day2, 13 µl of Buffer A was added to each well with 1.25 µl of Gapfill Enzyme mix. 9 µl 
is taken to each of two wells in a 96-well plate.  MIP probes were circularized by 4ul of 
di-nucleotide (dATP with dTTP, dCTP with dGTP) mix at 58○C for 10 min. The 
uncircularized probes and genomic DNA were eliminated by addition of 4 ul of 
Exonuclease Mix and incubation at 37oC for 15 min, followed by heat-killing of 
enzymes. The circularized probes were linearized by the addition of Cleavage Enzyme 
Mix at 37oC for 15 min, then subjected to universal primer amplification for 18 cycles at 
95oC 20 sec, 64oC 40 sec and 72oC 10 sec. For the labeling reaction, the product was 
further amplified with the label primers for 10 cycles, and then subjected to cleavage by 
Digest Enzyme Mix at 37○C for 2 hours. To hybridize, the cleaved MIP products were 
mixed with hybridization cocktail, denatured and hybridized to 70K Universal Taq arrays 
at 39oC for 16 h (two arrays per sample).  The overnight hybridized arrays were washed 
on GeneChip® Fluidics Station FS450 and stained by SAPE at 5ng/ml (Invitrogen). 
 
Copy number estimation was obtained from the hybridization signals as described 
previously, but with the following modifications [10].  Given that in this work no multi-
color readout was present (but rather single color readout on two arrays), no spectral 
overlap was present, therefore the color-seperation step was omitted.  In addition instead 
of the linear calibration of the allele signals, Langmuir correction was done [15]. 
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Generation of Spike-In Samples 
A panel of 80 PCR products representing genomic regions containing MIPs on 
chromosome 2 were PCR amplified from CEPH1341.14 (NA06985) using an ABI 9700 
thermocycler (initial denaturation of 95°C for 5 minutes, 95°C for 30 s, 58°C for 30 s, 
72°C for 60 s for 30 cycles; final extension at 72°C for 7 minutes).   The products were 
purified using a MinElute 96 UF PCR Purification plate (Qiagen) and resuspended in TE.  
The purified products were quantitated on a fluorometer using the Quant-It™ dsDNA 
Assay Kit (Invitrogen).  Purified PCR products were then pooled into 10 tubes, each 
containing 8 different products (supplementary Table 2).  Each pooled tube of probes was 
then serially diluted 2-fold into a series of spike-in tubes containing 150 ng of genomic 
DNA from CEPH1341.02 (NA06991) (supplementary Table 2).  The genomic DNA 
samples were chosen so that the spike-in PCR products from CEPH1341.14 represented a 
single allele, while the genomic DNA from CEPH 1341.02 was heterozygous, allowing 
for discrimination of allele specific amplification. 
Sequence Analysis of Aberrant MIPs 
PCR products were amplified using primers designed to span sequences containing MIPs 
that did not hybridize as expected (supplementary Table 3).  Amplification was carried 
out in a 50 ul reaction (initial denaturation of 95°C for 5 minutes, 95°C for 30 s, 58°C for 
30 s, 72°C for 60 s for 30 cycles; final extension at 72°C for 7 minutes) and products 
were purified using a MinElute 96 UF PCR Purification plate (Qiagen) and resuspended 
in TE.  The purified products were sequenced using an Applied Biosystems 96 capillary 
3730xl DNA Analyers and the forward and reverse primers used during amplification. 
Identification of LOH without matched normal tissue 
 
Genotyping metrics from the traditional MIP method were applied to each observation 
and estimated genotypes (AA, AB, or BB) were determined for each MIP in each of 5 
replicated tumor samples. Data are provided as supplementary file 1. Regions of the 
genome that show clear evidence for decreases in copy number are easily observed with 
the decrease in copy number equivalent to 1.5 total copies, (1 copy of one allele and 0.5 
copies of the other, or for homozygous alleles 1.5 total copies). No regions of the genome 
in any of the 5 samples analyzed appear to have ~1 copy of the higher allele and ~0 
copies of the lower allele. 
 
List of Abbreviations 
ACN Allele Copy Number 
MIP Molecular Inversion Probe 
CGH Comparative Genome Hybridization 
BAC Bacterial Artificial Chromosome 
LOH Loss of Heterozygosity 
SNP Single Nucleotide Polymorphism 
CNP Copy Number Polymorphism 
ROC Receiver Operator Characteristic 
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Figure legends 
Figure 1. Genomic view of samples with 1-5X chromosomes 
The X axis shows the markers in a genomic order, with each chromosome uniquely 
colored.  The Y chromosome depicts the measured copy number for each marker in linear 
scale.  The X chromosome is the last shown chromosome in orange color.  A) A male 
sample with 1 X chromosome. B) A female sample with 2X chromosomes. C) A cell line 
with 3 X chromosomes.  D) A cell line with 4 X chromosomes.  E) A cell line with 5 X 
chromosomes. 
 
Figure 2. ROC analysis 
The X axis is the rate of false positives (in log10), computed as the proportion of 
autosomal marker that have copy number below any given threshold (for the 1X 
calculation). The Y axis depicts sensitivity, defined as the proportion of X chromosome 
markers that have copy number values below the same threshold (for the 1X calculation).  
The curve is generated by calculating these values at many different thresholds.  The 
curves from the 3X, 4X, and 5X cell lines were generated in an analogous fashion. 
 
Figure 3. ROC analysis for individual samples 
The X axis is generated in the same fashion as Figure 2 with the exception the curve for 
each sample is plotted separately.  The average curve is the thick black line.  
 
Figure 4. ROC analysis for allele ratio 
The X axis is the rate of false positives (in log10), computed as the proportion of 
autosomal marker that have allele ratio above a threshold. The Y axis depicts sensitivity, 
defined as the proportion of X chromosome markers in the cell line carrying 3X 
chromosomes that have copy number values below the same threshold.  The curve is 
generated by calculating these values at many different thresholds. 
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Figure 5. ROC analysis for 2-marker smoothing 
The same ROC analysis as described in Figure 2 is performed here using the same set of 
markers (~40K) as well as using a larger number of markers (~48K).  The ROC analysis 
was also performed using 2-marker smoothing.  In this case the smoothing was done for 
two random markers.  If we assume that the performance of individual markers is not 
correlated with their position (i.e. markers close together are likely to have similar 
performance) then this should be an accurate reflection of the resultant performance with 
adjacent markers smoothing.  We note that at the lower false positive rate for the 2-
markers smoothed data, the curve is not smooth given low statistics. 
 
Figure 6. Amplification in MCF7 
A) The X axis shows the markers in a genomic order, with each chromosome uniquely 
colored.  The Y chromosome depicts the measured copy number for each marker in log2 
(the log scale is used given the high dynamic range).  The arrow depicts the position of 
the locus that was also analyzed by real time PCR. B) Focused view around the 
amplification site that was checked with real time PCR.  As can be seen there are several 
sites of amplifications of different levels.  The black bar identifies the region for which 
average copy number was calculated. 
 
Figure 7. Estimation of copy number of the spikes 
The X-axis shows the expected copy number (in log2) for the individual spiked in PCR 
fragments, and the Y-axis shows the observed copy number for the same spiked in 
fragments.  The linear fit (r2=0.82) is only for spikes with expected copy number <64 (26) 
because of the clear saturation above that point.  
Figure 8. Allele Copy Number distributions and reproducibility 
Copy number measurements for tumor sample 47 (fairly normal genome content) is 
shown in panel A with genotypes AA colored red, AB colored blue, and BB colored 
green. Allele copy number measurements for tumor 45 (replicate 1) are plotted in panels 
B and C. In panel B, genotypes derived from replicate 1 are colored AA red, AB blue, 
and BB green. Panel C is the genotypes from replicate 2 in the same color scale. 
 
Figure 9. Visualization of individual copy number measurements without matched 
normal samples 
Panels A-C show copy number measurements for tumor 48 in genome order from 
chromosome 1 on the left to chromosome 22 and X on the right. Data are segregated by 
higher and lower copy number estimates and by homozygosity or heterozygosity. Blue 
and orange data points are the higher allele copy measurement while green and red data 
points are the lower copy number measurements. Blue and red data points are 
homozygous alleles while orange and green are heterozygous alleles. Panel A shows the 
entire genome. Panel B shows chromosome 1 through the first 100Mbp of chromosome 
5. Panel C shows chromosome 1 and the first 50Mbp of chromosome 2. Panel C shows 
key features of ACN data. An amplification is seen near position 5e7. An extra copy of 
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1q is seen between ~1.5e8 and 2.5e8.  A deletion of 1 copy is seen on the p arm of 
chromosome 2 between ~2.5e8 and 3e8 (observed in panel B as a complete loss of one 
copy of chromosome 2). Panel D shows a small section of chromosome 5 from tumor 44. 
One chromosome is at copy number 0.5 across this region, which indicates a loss of that 
chromosome. The black arrow shows a region at total copy number 2, which likely 
includes reduplication of the lost chromosome in the tumor. The red arrow shows a 
region where both alleles are at copy number 0.5 suggesting a complete deletion. The 
green arrow shows copy number 1 for the yellow alleles 
 
 
Tables 
Table 1 
Sensitivity at 50% Specificity 
 1 Marker 2 Markers 
40K (75% of data) 1.7E-03 4.0E-05 
48K (90% of data) 2.7E-03 7.1E-05 
 
Table 2 
Expected vs. Measured Copy Number 
 Expected copy 
number 
Measured copy 
number 
Relative standard 
deviation 
1 (9) 1.055 0.14 
2 (15) 1.997 0.12 
3 (2) 3.104 0.11 
4 (2) 3.981 0.10 
5 (2) 4.956 0.10 
 
Table 3 
Allele Copy Number in Spiked Samples 
Copy_A Copy_B 
199.2 1.3 
184.8 1.1 
169.4 1.5 
141.8 1.3 
139.7 0.8 
105.4 1.0 
84.6 1.0 
80.2 0.9 
73.8 0.8 
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73.0 0.9 
70.6 1.1 
64.5 1.0 
60.8 1.0 
59.8 1.3 
57.4 0.8 
54.6 1.1 
52.8 1.0 
43.3 0.8 
39.2 1.1 
38.8 0.9 
33.4 0.8 
27.5 0.8 
25.7 0.9 
18.7 1.2 
14.3 0.7 
12.9 0.9 
11.3 1.0 
 
Table 4 
Genotyping disagreements between replicated samples 
Sample Discordant Calls Total Calls Discordant Rate 
44 643 50236 1.3% 
45 419 50260 0.8% 
46 271 50250 0.5% 
47  258 50244 0.5% 
48  393 50242 0.8% 
 
Additional Files 
Supplementary file 1. XLS. Allelic Copy Number of breast tumors. Replicated CAN data 
for five breast cancers. Data are filtered to use only high quality MIPs (90% or 
greater call rate, less than 12% copy number variation). 
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